Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K Grasing

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
The American Journal of Gastroenterology|March 1, 1996
Selective blockade of cholecystokinin type B receptors with L-365,260 does not impair gallbladder contraction in normal humansK Grasing, D Freedholm, M G Murphy, et al.
Journal of Clinical Pharmacology|April 1, 1996
Human pharmacokinetics and tolerability of L-365,260, a novel cholecystokinin-B antagonistK Grasing, M G Murphy, J Lin, et al.
Pharmaceutical Research|November 1, 1993
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humansH Cheng, S C Sutton, J D Pipkin, et al.
Clinical Pharmacology and Therapeutics|July 3, 1999
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humansJ I Schwartz, C C Chan, S Mukhopadhyay, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
The American Journal of Gastroenterology|March 1, 1996
Selective blockade of cholecystokinin type B receptors with L-365,260 does not impair gallbladder contraction in normal humansK Grasing, D Freedholm, M G Murphy, et al.
Journal of Clinical Pharmacology|April 1, 1996
Human pharmacokinetics and tolerability of L-365,260, a novel cholecystokinin-B antagonistK Grasing, M G Murphy, J Lin, et al.
Pharmaceutical Research|November 1, 1993
Evaluation of sustained/controlled-release dosage forms of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors in dogs and humansH Cheng, S C Sutton, J D Pipkin, et al.
Clinical Pharmacology and Therapeutics|July 3, 1999
Cyclooxygenase-2 inhibition by rofecoxib reverses naturally occurring fever in humansJ I Schwartz, C C Chan, S Mukhopadhyay, et al.
Pageof 3